Finally, to explore the role of DGAT isoforms in LD formation in an Elovl5-dependent manner, we inhibited DGAT1 and DGAT2 activity with pharmacological agents A922500 (DGAT1i) and PF-06424439 (DGAT2i) respectively and observed a decrease in LD accumulation in Elovl5-depleted breast cancer cells treated with the DGAT inhibitors analyzed by fluorescence microscopy or flow cytometry (Fig. 5K and Supplementary Fig. S5I–N). Here, DGAT2 is linked to breast carcinoma.